The Rutgers NJMS Clinical Genomics is the successor of the UMDNJ Institute of Genomic Medicine (founded in 1990). Our current staff of includes: board-certified clinical geneticists and lab directors, board-certified genetic counselors, social workers and registered dietitians.
We are committed to enabling translational research and personalized medicine through biomarker discovery, clinical development and commercialization. To this end, Rutgers NJMS Clinical Genomics functions as an academic contract research organization (CRO) dedicated to biomarker discovery and the clinical evaluation of biomarkers. As a CRO, we operate CLIA certified CAP accredited research and diagnostic laboratories. The patient population has exceptional ethnic diversity. Our staff of physicians, clinical geneticists and genetic counselors has extensive experience in patient care and education.
Support specialty clinics for neurofibromatosis (Peyman Bizargity, M.D., Director, Division of Clinical Genetics) autism, cranial facial disorders, sickle cell disease, cystic fibrosis and muscular dystrophy
Next Generation Sequencing, Microarray and other equipment for genomic research (single cell analysis, expression profiling and genotyping).
Offering clinical development of diagnostic biomarkers discovered by university faculty and industry partners in our CLIA-certified labs. Providing biomarker discovery and development services to biotechnology and pharmaceutical companies.